Do the Large Benefits Justify the Large Costs of Adjuvant Breast Cancer Trastuzumab?-Reference-Cited by-同舟云学术

Do the Large Benefits Justify the Large Costs of Adjuvant Breast Cancer Trastuzumab?

Published:2007-02-09 Issue:6 Volume:25 Page:611-613
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Hillner Bruce E.¹,Smith Thomas J.¹

Affiliation:

1. Department of Internal Medicine and the Massey Cancer Center, Virginia Commonwealth University, Richmond, VA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2006.09.3542

Reference13 articles.

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

2. Cost-effectiveness of new guidelines for adjuvant systemic therapy for patients with primary breast cancer

3. World Health Organization.Macroeconomics and Health: Investing in Health for Economic Development: Report of the Commission on Macroeconomics and Health . Geneva, World Health Organization, 2001

4. A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/neu–Positive Breast Cancer

5. Cost Effectiveness of Adjuvant Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Post-Transplant Hepatocellular Carcinoma Surveillance;Annals of Surgery;2021-11-11

2. Clinical utility of whole-genome sequencing in precision oncology;Seminars in Cancer Biology;2021-06

3. Price Transparency for Whom? In Search of Out-of-Pocket Cost Estimates to Facilitate Cost Communication in Cancer Care;PharmacoEconomics;2018-02-02

4. 4th symposium on primary breast cancer in older women. Theme: putting personalized care into practice (Held: 3 March 2017);Breast Cancer Management;2017-05

5. SAR and QSAR study on the bioactivities of human epidermal growth factor receptor-2 (HER2) inhibitors;SAR and QSAR in Environmental Research;2017-02-01